Market access is now too complex for historical analogues — and AI is the only tool that can model what comes next.
Feature|Articles|September 15, 2026
Pharma Now Has Two Audiences — People and Machines: Q&A with Stewart Gandolf
Author(s)Mike Hollan, Stewart Gandolf
Pharma brands with all the right information are still invisible to AI — and why silence is the bigger risk than inaccuracy.
Advertisement
Advertisement
AI became the most common way people search the internet. Not surprisingly, the new technology impacted that way that people search, including patients. Now, instead of keyword searching, many experts are saying that people search by question.
Related to this article
Clinical data harmonization is the real bottleneck standing between life sciences companies and AI's transformative potential.
Inovalon's Jen Lamppa on why AI's ability to extract insights from unstructured clinical data is foundational to making RWD usable in trials.
The best CI partner isn't the one with the most data — it's the one willing to tell you your assumptions are wrong.
Inovalon's Jen Lamppa on why FDA's acceptance of RWD downstream is a call to action for sponsors to start using it upstream in trial design.
AbbVie partners with Iambic to deploy its AI molecular superintelligence platform, while Telix Pharmaceuticals agrees to acquire radioisotope leader ITM.
Inovalon's Jen Lamppa on how real-time clinical data feeds validate patient eligibility at enrollment — reducing burden while improving accuracy.
FDA approves Ultragenyx's Fayuvi as the first treatment for Sanfilippo syndrome type A, Lisata Therapeutics acquires Marea Therapeutics as mAbxience partners with Sandoz on a hemophilia A biosimilar, and Joe Cunningham argues that executive drug-pricing deals alone won't fix costs.
Advertisement
Advertisement